Literature DB >> 25118124

Rate of percutaneous coronary intervention for the management of acute coronary syndromes and stable coronary artery disease in the United States (2007 to 2011).

Luke K Kim1, Dmitriy N Feldman2, Rajesh V Swaminathan2, Robert M Minutello2, Jake Chanin2, David C Yang2, Min Kyeong Lee3, Konstantinos Charitakis2, Ashish Shah2, Ryan K Kaple2, Geoffrey Bergman2, Harsimran Singh2, S Chiu Wong2.   

Abstract

Although the benefit of percutaneous coronary interventions (PCIs) for patients presenting with acute coronary syndromes (ACS) has been established in numerous studies, the role of PCI in stable coronary artery disease (CAD) remains controversial. With the publication of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluations trial and the appropriate use criteria for coronary artery revascularization, we sought to examine the impact of these treatment strategies and guidelines on the current practice of PCI in United States. We conducted a serial cross-sectional study with time trends of patients undergoing PCI for ACS and stable CAD from 2007 to 2011. The annual rate of all PCI decreased by 27.7% from 10,785 procedures per million adults per year in 2007 to 2008 to 7,801 procedures per million adults per year in 2010 to 2011 (p=0.03). Although there was no statistically significant decrease in the PCI utilization for ACS from 2007 to 2011, PCI utilization for stable CAD decreased by 51.7% (from 2,056 procedures per million adults per year in 2008 to 992 procedures per million adults per year in 2011, p=0.02). Hospitals with a higher volume of PCI experienced a more significant decrease. Decrease in PCI utilization for stable CAD was statistically significant for patients with Medicare and private insurance/health maintenance organization (44.5%, p=0.03 and 59.5%, p=0.007, respectively). In conclusion, the rate of PCI decreased substantially starting from 2009 in the United States. Most of the decrease was attributed to the reduction in PCI utilization for stable CAD.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25118124     DOI: 10.1016/j.amjcard.2014.07.013

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

1.  Outcomes of PCI in Relation to Procedural Characteristics and Operator Volumes in the United States.

Authors:  Alexander C Fanaroff; Pearl Zakroysky; David Dai; Daniel Wojdyla; Matthew W Sherwood; Matthew T Roe; Tracy Y Wang; Eric D Peterson; Hitinder S Gurm; Mauricio G Cohen; John C Messenger; Sunil V Rao
Journal:  J Am Coll Cardiol       Date:  2017-06-20       Impact factor: 24.094

2.  Does cardiology hold pharmacogenetics to an inconsistent standard? A comparison of evidence among recommendations.

Authors:  Jasmine A Luzum; Jason C Cheung
Journal:  Pharmacogenomics       Date:  2018-09-10       Impact factor: 2.533

3.  Target Lesion Calcium Arc Influence the Performance of Stenting.

Authors:  Pengfei Dong; Shengmao Lin; David L Wilson; Hiram G Bezerra; Linxia Gu
Journal:  2017 Des Med Devices Conf (2017)       Date:  2017-04

4.  Co-registration of pre- and post-stent intravascular OCT images for validation of finite element model simulation of stent expansion.

Authors:  Yazan Gharaibeh; Juhwan Lee; David Prabhu; Pengfei Dong; Vladislav N Zimin; Luis A Dallan; Hiram Bezerra; Linxia Gu; David Wilson
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2020-02-28

5.  Impact and trends of intravascular imaging in diagnostic coronary angiography and percutaneous coronary intervention in inpatients in the United States.

Authors:  Nathaniel R Smilowitz; Divyanshu Mohananey; Louai Razzouk; Giora Weisz; James N Slater
Journal:  Catheter Cardiovasc Interv       Date:  2018-07-18       Impact factor: 2.692

6.  Treatment of Higher-Risk Patients With an Indication for Revascularization: Evolution Within the Field of Contemporary Percutaneous Coronary Intervention.

Authors:  Ajay J Kirtane; Darshan Doshi; Martin B Leon; John M Lasala; E Magnus Ohman; William W O'Neill; Adhir Shroff; Mauricio G Cohen; Igor F Palacios; Nirat Beohar; Nir Uriel; Navin K Kapur; Dimitri Karmpaliotis; William Lombardi; George D Dangas; Manish A Parikh; Gregg W Stone; Jeffrey W Moses
Journal:  Circulation       Date:  2016-08-02       Impact factor: 39.918

7.  Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.

Authors:  Peng Dong; Xinchun Yang; Suyan Bian
Journal:  Med Sci Monit       Date:  2016-12-15

8.  Regional and hospital variations in the extent of decline in the proportion of percutaneous coronary interventions performed for nonacute indications - a nationwide population-based study.

Authors:  Fu-Wen Liang; Tsung-Hsueh Lu; Hsin-Min Wu; Jo-Chi Lee; Wei-Hsian Yin
Journal:  BMC Cardiovasc Disord       Date:  2017-06-09       Impact factor: 2.298

Review 9.  Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in Chinese patients with acute coronary syndrome: A systematic review and meta-analysis.

Authors:  Ziliang Ye; Haili Lu; Qiang Su; Wenqin Guo; Weiran Dai; Hongqing Li; Huafeng Yang; Lang Li
Journal:  PLoS One       Date:  2017-02-23       Impact factor: 3.240

10.  Descriptive Study on the Korean Status of Percutaneous Coronary Intervention Using National Health Insurance Service-National Sample Cohort (NHIS-NSC) Database: Focused on Temporal Trend.

Authors:  Jidong Sung; Kyung Pyo Hong
Journal:  Korean Circ J       Date:  2019-08-02       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.